Maintenance therapy for duodenal ulcer: a randomized controlled comparison of seven forms of treatment.
OBJECTIVE
We performed a randomized controlled trial to compare the efficacy of seven forms of maintenance treatment of duodenal ulcer, including a mealtime regimen of antacids.


METHODS
We randomized 785 patients with healed duodenal ulcer to receive: (1) no treatment; (2) mealtime antacids with an acid-neutralizing capacity of 80 mmol/day; (3) an antidepressant, trimipramine 25 mg; (4) an anticholinergic, pirenzepine 50 mg; (5) cimetidine 200 mg; (6) cimetidine 400 mg; (7) ranitidine 150 mg; or (8) sucralfate 1 g twice a day. Symptomatology and side effects were assessed every 2 months and endoscopy was performed every 4 months up to 1 year.


RESULTS
The patients were comparable in the majority of clinical characteristics before entry. The cumulative percentages of patients with relapse of ulcers at 12 months by life-table analysis were 61% with no treatment, 38% with mealtime antacids, 60% with trimipramine, 52% with pirenzepine, 46% with cimetidine 200 mg, 44% with cimetidine 400 mg, 30% with ranitidine 150 mg, and 40% with sucralfate. Cimetidine 400 mg, antacids, ranitidine 150 mg, and sucralfate were significantly better than no treatment and the other forms of treatment. Ranitidine was significantly better than antacids, cimetidine, and sucralfate in preventing endoscopically documented duodenal ulcer relapse by multiple comparison at 12 months, but not by life-table analysis nor when symptomatic relapses were compared. No significant difference was detected among antacids, cimetidine, and sucralfate. No major side effects occurred with the seven forms of treatment, but those receiving antacids had the highest incidence of minor adverse events (26%).


CONCLUSIONS
This study suggests that mealtime antacids are as effective as H2-receptor antagonists and sucralfate in the maintenance treatment of duodenal ulcer disease, but have to be taken three times a day and had the highest incidence of reported minor adverse events. The relapse rate was lower with ranitidine than with cimetidine, sucralfate, and antacids, but the difference was small and may not be clinically important.
Hui
W M
WM
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
Lam
S K
SK
Lok
A S
AS
Ng
M M
MM
Lai
C L
CL
D000328:Adult; D000863:Antacids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002927:Cimetidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D016099:Endoscopy, Gastrointestinal; D005260:Female; D006723:Hong Kong / Q000453:epidemiology; D006785:Hospitals, University; D006801:Humans; D015993:Life Tables; D016015:Logistic Models; D008297:Male; D010890:Pirenzepine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011899:Ranitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D012307:Risk Factors; D013392:Sucralfate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014299:Trimipramine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000863:Antacids; D010890:Pirenzepine; D013392:Sucralfate; D014299:Trimipramine; D002927:Cimetidine; D011899:Ranitidine